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Abstract
Most women with epithelial ovarian cancer (EOC) suffer from peritoneal carcinomatosis upon first clinical presentation. 
Extensive peritoneal carcinomatosis has a poor prognosis and its pathophysiology is not well understood. Although treatment 
with systemic intravenous chemotherapy is often initially successful, peritoneal recurrences occur regularly. We hypoth-
esized that insufficient or poorly-perfused microvasculature may impair the therapeutic efficacy of systemic intravenous 
chemotherapy but may also limit expansive and invasive growth characteristic of peritoneal EOC metastases. In 23 patients 
with advanced EOC or suspicion thereof, we determined the angioarchitecture and perfusion of the microvasculature in 
peritoneum and in peritoneal metastases using incident dark field (IDF) imaging. Additionally, we performed immunohisto-
chemical analysis and 3-dimensional (3D) whole tumor imaging using light sheet fluorescence microscopy of IDF-imaged 
tissue sites. In all metastases, microvasculature was present but the angioarchitecture was chaotic and the vessel density and 
perfusion of vessels was significantly lower than in unaffected peritoneum. Immunohistochemical analysis showed expression 
of vascular endothelial growth factor and hypoxia inducible factor 1α, and 3D imaging demonstrated vascular continuity 
between metastases and the vascular network of the peritoneum beneath the elastic lamina of the peritoneum. We conclude 
that perfusion of the microvasculature within metastases is limited, which may cause hypoxia, affect the behavior of EOC 
metastases on the peritoneum and limit the response of EOC metastases to systemic treatment.
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Introduction
Epithelial ovarian cancer (EOC) has the highest mor-
tality of all gynecological malignancies. Worldwide, an 
estimated 140,000 women die annually from this type of 
cancer [1, 2]. At the time of first clinical presentation, over 
70% of women with EOC have advanced stage disease 
that has spread beyond the pelvis to the peritoneum of 
the abdominal cavity. This peritoneal carcinomatosis (PC) 
produces malignant ascites and impairs bowel movements, 
which has a severe impact on quality of life and survival 
[3, 4].
PC poses a challenge for clinicians and researchers. 
Complete cytoreductive surgery is difficult, especially 
when the small bowel is affected by PC. Although sys-
temic intravenously (IV)-administered chemotherapy is 
often initially effective, recurrences occur in more than 
60% of women [3, 5]. Moreover, interactions between met-
astatic EOC cells and the peritoneum are still an enigma: 
it is unclear why peritoneal metastases of EOC remain 
small (1–2  mm3) and why spontaneous invasive growth 
of EOC cells through the parietal peritoneal layers does 
not occur [6-8].
Formation of new blood vessels (angiogenesis) and 
a new vascular network is required for tumors to grow 
larger than 1–2  mm3 and is considered a prerequisite for 
tumor progression [9-13]. Previous immunohistochemical 
studies reported increased vascularization in metastases 
and the surrounding peritoneum [14-16]. However, the 
perfusion of the microvasculature was not investigated in 
these ex vivo studies and it has not been clearly described 
whether there is vascular continuity between peritoneal 
metastases and the vascular network of the submesothelial 
stroma of the peritoneum [6].
Incident dark field (IDF) imaging enables real-time 
in  vivo visualization of the human microvasculature, 
allowing quantification of perfusion [17]. We recently 
visualized the peritoneal microvasculature with IDF imag-
ing and we showed that the peritoneal microvasculature 
consists of well-perfused vessels forming an organized 
network, often embedded in fat tissue [18].
We hypothesized that the microvasculature in peritoneal 
EOC metastases is insufficient, which may not only limit 
expansive and invasive growth, but also impair the thera-
peutic efficacy of systemic IV chemotherapy. Therefore, 
the present study aimed to investigate the angioarchitec-
ture and perfusion of the microvasculature in peritoneum 
and peritoneal metastases of EOC. We performed IDF 
imaging in patients with and without EOC and/or PC and 
we performed histology and immunohistochemistry on 
tissue derived from IDF-imaged sites. Three-dimensional 
(3D) whole tumor imaging was performed using light 
sheet fluorescence microscopy, to allow a circumferen-
tial analysis of metastases and to investigate whether the 
microvasculature of metastases is continuous with that of 
the surrounding submesothelial stroma.
Materials and methods
Participants
In this prospective single-center observational study, we 
recruited women undergoing either cytoreductive surgery 
for advanced EOC or exploratory laparotomy because of 
a suspicious adnexal mass. This study was performed at 
the Department of Gynecological Oncology of the Nether-
lands Cancer Institute, Antoni van Leeuwenhoek Hospital, 
Amsterdam, The Netherlands. Participant characteristics 
were retrieved from medical charts. Exclusion criteria were 
recent cardiovascular events, use of anticoagulant or immu-
nosuppressant medication and language barriers compromis-
ing informed consent. Participants that were treated with 
neoadjuvant chemotherapy were not excluded. The study 
was in compliance with ethical principles and regulatory 
requirements according to the Declaration of Helsinki. All 
study participants received a verbal and written explana-
tion of the study procedures. Informed consent was obtained 
from all individual participants included in the study. The 
protocol was reviewed by the Institutional Review Board of 
the Antoni van Leeuwenhoek Hospital and permission was 
granted on August 16, 2017.
Vital parameters
Parameters such as heart rate, blood pressure, body tem-
perature, hemoglobin levels and hematocrit were acquired 
at the time of microcirculatory imaging. An hypotensive 
event was characterized as a drop of > 20% in mean arterial 
pressure or a mean arterial pressure of < 60 mmHg [19]. 
Use of inotropic medicine was recorded as total quantity of 
administered drug until time of imaging.
Microcirculatory imaging
The microcirculation was visualized with IDF imaging 
(CytoCam; Braedius Medical, Huizen, The Netherlands) 
[20]. The CytoCam is a third-generation hand-held video 
microscope which weighs 120 g and is shaped like a pen 
(length 220 mm, diameter 23 mm). The CytoCam pro-
duces green light (530 nm) produced by concentrically 
placed light-emitting diodes (LEDs), providing epi-illumi-
nation of the tissue. The green light is absorbed by hemo-
globin in erythrocytes, allowing erythrocytes to be imaged 
and recorded as a real-time representation of the local 
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microcirculation [21]. The CytoCam uses a short illumina-
tion pulse time (2 ms) and a high spatial (14 megapixels) 
and temporal (60 frames per second) resolution. A total field 
of view of 1.55 × 1.16 mm was recorded at a × 4 optical 
magnification. The system provides an optical resolution of 
more than 300 lines/mm. The CytoCam is connected to a 
device controller which in turn is connected to a laptop, to 
record and store video clips as digital audio video interleave 
(AVI) files [20].
Data acquisition
Microcirculatory imaging was performed during surgery as 
soon as the surgical retractor (Omni-Tract Surgical, St. Paul, 
MN, USA) was positioned, either before cytoreductive sur-
gery or after removal of the enlarged adnexa. The latter was 
sometimes necessary to obtain clear vision and access to the 
pelvic peritoneum. During imaging, the CytoCam was cov-
ered with a sterile latex-free probe cover (Microtek Medical, 
Zutphen, The Netherlands). The camera was operated by 
trained researchers (AWK, LMCV or CARL). Excess peri-
toneal fluid was removed using gauze or suction. To pre-
vent pressure-induced artefacts, the camera was placed in 
light contact with the peritoneal surface in a perpendicular 
position. In case of a macroscopically normal aspect of the 
peritoneum, a total of 6 video clips were recorded on spe-
cific locations: (1) the paracolic gutter left and right, (2) the 
ovarian fossa left and right, (3) on top of the bladder left and 
right. In participants with PC, video clips were recorded by 
placing the CytoCam directly on top of metastatic deposi-
tions, and adjacent to the tumors (< 1–2 cm). All imaged 
metastases had a diameter ≥ 1 mm. Aforementioned specific 
locations of the peritoneum were also imaged in participants 
with PC. At each area of interest, one recording of 3 s was 
made, unless imaging was suboptimal (e.g. due to image 
drifting or loss of focus; in those cases, a second or even 
third recording was performed).
Quality score
The quality of each video clip was assessed using a scoring 
system based on 6 parameters (illumination, focus, content, 
stability, pressure, duration) [22]. When not all 6 parameters 
scored positively, the recording was not analyzed.
Quantification of the microcirculation 
and comparison of microcirculatory parameters
The microcirculation was quantified in the capillaries only, 
since these are the (functional) exchange vessels [23]. We 
considered any vessel with a diameter of < 20 µm to be a 
capillary, which is also the general consensus in the litera-
ture [23-25]. We calculated the total vessel density (TVD, 
mm/mm2) and the quality of the blood flow in the capillaries 
(0, no flow; 1, sluggish flow; 2, intermittent flow; 3, continu-
ous flow). Subsequently, the perfused vessel density (PVD, 
mm/mm2) was determined and the percentage of perfused 
vessels (PPV, %) was calculated as ratio of all vessels with 
flow (score ≥ 1) and TVD.
Image analysis
Analysis of images was performed offline. The analyst was 
blinded for the macroscopic aspects of the imaged sites. 
Above-mentioned parameters PVD, PPV and TVD were 
calculated with the use of software-assisted analysis (AVA 
3.2; Automated Vascular Analysis, Amsterdam UMC, loca-
tion AMC, Amsterdam, The Netherlands).
Statistical analysis
Descriptive statistics were used to analyze the demographic 
variables. Non-normally distributed data were presented 
as medians with interquartile ranges. The non-parametric 
Mann–Whitney U test was used for comparing medians of 
TVD, PVD and PPV across the different non-normally dis-
tributed groups. Normally-distributed data were presented as 
means with standard deviations. A two-sided P value < 0.05 
was considered to indicate statistically significant differ-
ences. All data were analyzed using SPSS, version 23.0 for 
Windows (IBM, Armonk, NY, USA). We did not perform 
a power calculation prior to the study, since this was a first 
pilot study with unknown effect sizes. We aimed to include 
at least 10 participants with PC. However, because it was not 
always known prior to inclusion whether PC was present, it 
was unknown how many participants had to be included to 
reach the target of 10 participants with PC.
Histology
Biopsies were taken from metastases and from peritoneum 
with a normal aspect (control), all from different patients. 
Prior to resection of the biopsies, their localization was 
imaged with the CytoCam. Tissue samples were fixed using 
buffered 4% para-formaldehyde immediately after harvest-
ing. Samples were either used for (1) immunohistochemistry 
and conventional 2D microscopy or (2) 3D whole tumor 
imaging using light sheet fluorescence microscopy.
Immunohistochemistry
Chromogenic immunohistochemistry was performed on 
5 µm-thick paraffin sections of the tissue samples using 
Benchmark ULTRA staining (Roche Diagnostics, Indianap-
olis, MN, USA), using the method that was recently shown 
to be the optimum immunohistochemical method to be 
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applied to paraffin sections [26]. Dewaxing was performed 
by incubation of the sections in xylene (VWR Chemicals, 
Atlanta, GA, USA) for 10 min and rinsing in 100% ethanol 
(Merck, Darmstadt, Germany). Sections were treated with 
100% methanol (Merck) containing 0.3% hydrogen peroxide 
(Merck) for 10 min to block endogenous peroxidase activity 
and to reduce non-specific background staining, followed 
by a washing step in distilled water. Antigen-retrieval was 
performed using Tris–EDTA buffer (pH 8.5) followed by a 
washing step in distilled water and 3 washing steps of 5 min 
each using Tris-buffered saline (TBS; pH 7.6) containing 
0.1% Triton-X (Sigma-Aldrich, St. Louis, MO, USA). Sec-
tions were encircled with a PAP pen (Dako, Glostrup, Den-
mark) and incubated using TBS containing 3% normal goat 
serum (Dako) and 0.1% Triton-X for 1 h to further reduce 
non-specific background staining and for permeabilization 
of the sections. Sections were subsequently incubated over-
night at 4 °C with primary antibodies against paired-box 
gene 8 (PAX-8 363M-15; clone MRQ50, dilution 1:50; 
Cellmarque, Rocklin, CA, USA), which specifically stains 
EOC cells, VEGF (sc-152; Santa Cruz, Biotechnology, Dal-
las, TX, USA), cluster of differentiation 31 (CD31; M0823, 
clone JC70A, dilution 1:250, Dako), which specifically 
stains endothelial cells [26-29]. Next, sections were incu-
bated with 3,3′-diaminobenzidine (Dako) for 10 min, fol-
lowed by one washing step with tap water to stop the peroxi-
dase enzyme reaction. Sections were then incubated for 30 s 
in hematoxylin (Sigma-Aldrich) for nuclear counterstaining. 
Sections were again placed in running tap water for 5 min 
and then in distilled water. Finally, sections were dehydrated 
by subsequently dipping in 70%, 96% and 100% ethanol 
(Merck) and 3 times dipping in xylene (VWR Chemicals). 
All incubations were performed at room temperature (RT) 
unless stated otherwise. An amplification step with a second-
ary horseradish peroxidase (HRP) antibody (poly-HRP) was 
performed on the PAX-8-stained sections. Finally, sections 
were covered with the synthetic mountant Pertex (Histolab, 
Götenburg, Sweden).
Fluorescence immunohistochemical staining of HIF-1α 
was performed, following the method as described by Hira 
et al. [30]. Paraffin sections were dewaxed by incubation of 
the sections in xylene (VWR) for 5 min, followed by rinsing 
in 100%, 96% and 70% ethanol (Merck), respectively. Anti-
gen-retrieval was performed in a microwave using 100 mM 
citrate buffer containing 0.1% Triton-X, pH 6.0, for 20 min 
at 98 °C, followed by cooling for 20 min and a washing step 
in PBS. Sections were encircled with a PAP pen (Dako) 
and incubated with PBS containing 10% normal goat serum 
(Dako) and 0.1% Triton-X for 1 h at RT, to reduce non-
specific background staining and for permeabilization of the 
sections. Sections were subsequently incubated overnight 
at 4 °C with primary antibody (mouse anti-human HIF-1α, 
Abcam (ab8366), dilution 1:100) diluted in PBS containing 
1% BSA. Sections were washed 3 times using PBS contain-
ing 1% BSA. Alexa Fluor 546-conjugated goat anti-mouse 
antibodies were used as secondary antibodies in a dilution 
of 1:200 in PBS containing 1% BSA for 1 h at RT. Next, 
sections were washed in PBS for 5 min and coverslipped 
using Prolong Gold mounting medium (Life Technologies, 
Carlsbad, CA, USA). Afterwards, sections were sealed with 
nail polish and dried overnight.
Control incubations were performed in the absence of 
the primary antibody. Chromogenic stained sections were 
analyzed by light microscopy (Olympus BX51 microscope, 
Leiderdorp, The Netherlands) and images were acquired 
using the Olympus cellSense Standard software. Fluores-
cence imaging was performed using a Nikon Eclipse Ti-E 
inverted microscope (Nikon Instruments, Melville, NY, 
USA) and the Nikon NIS-Elements AR 4.13.04 software.
3D whole tumor imaging using light sheet fluorescence 
microscopy
For 3D imaging, samples were treated according to the 
iDisco protocol with minor adaptions [31]. Samples were 
dehydrated with methanol/H2O series: 20%, 40%, 60%, 
80%, 100%, 100%; 1 h each and were incubated overnight 
in 66% dichloromethane (DCM)/33% methanol at RT under 
continuous slow shaking. Samples were then washed twice 
in 100% methanol at RT, subsequently chilled at 4 °C and 
overnight bleached in fresh 5%  H2O2 in methanol. Next day, 
samples were rehydrated with methanol/H2O series: 80%, 
60%, 40%, 20%, PBS; 1 h each at RT and subsequently 
washed 2 × for 1 h in PBS + 0.2% Triton X-100 at RT. 
For immunolabeling, samples were incubated for 2 days in 
permeabilization solution (PBS, 0.4% Triton X-100, 20% 
DMSO, 0.3 M glycine) at 37 °C and subsequently blocked in 
blocking solution (PBS/0.2% Triton X-100/10% DMSO/6% 
donkey serum) for 1 day at 37 °C. Samples were washed 
in PBS/0.2% Tween-20 with 10 μg/ml heparin (PTwH) 
for 1 h twice, then incubated in mouse anti-human CD31 
antibodies (clone EN4; dilution 1:200; Monosan; Sanbio; 
Uden) in PTwH/5% DMSO/3% donkey serum at 37 °C for 
4 days under continuous shaking. Samples were washed with 
PTwH for 10 min, 15 min, 30 min, 1 h and every 2 h until 
the end of the day and incubated with secondary antibody 
in PTwH, 3% donkey serum for 4 days at 37°, under con-
tinuous slow shaking. Samples were washed in PTwH for 
10 min, 15 min, 30 min, 1 h, every 2 h and overnight at RT. 
After immunolabeling, samples were embedded in 2% low 
melting agarose (Sigma-Aldrich) to facilitate handling of 
the samples and dehydrated in methanol/H2O series: 20%, 
40%, 60%, 80%, 100%, 1 h each at RT. Samples were left 
overnight in 100% methanol and the next day incubated for 
3 h in 66% DCM/33% methanol at RT, 2 × in 100% DCM 
(Sigma) for 15 min and finally incubated in dibenzyl ether 
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(Sigma) (no shaking) until samples were transparent. Upon 
clearing, samples were immediately imaged with light sheet 
fluorescence microscopy using the Ultramicroscope (LaVi-
sion BioTec, Bielefeld, Germany) [28]. Inspector Software 
(LaVision, BioTec) was used for settings adjustment and 
image acquisition. Image analysis was performed using 
Imaris 9.2 or higher [28].
Results
Twenty-three participants were included in the study. Par-
ticipant and disease characteristics as well as perioperative 
parameters that may have affected the peritoneal microcir-
culation are summarized in Table 1.
A total of 199 video clips were recorded, of which 118 
videos were accepted for analysis after quality assessment. 
Exclusion of videos most often occurred because of insuf-
ficient stability [32]. Based on histopathology of the tumor 
and macroscopic aspects of the peritoneum, participants 
were divided into 3 groups: benign (n = 3, 17 video clips), 
EOC with no visible PC (n = 10, 55 video clips) and EOC 
with visible PC (n = 10, 46 video clips).
IDF imaging: qualitative analysis 
of angioarchitecture
IDF imaging of the microvasculature revealed extensive 
differences between the microvascular networks in perito-
neum and peritoneal metastases (Fig. 1A–D). The angio-
architecture in peritoneum without peritoneal metastases 
was characterized by an organized network structure and 
was comparable in all groups (benign, EOC without PC and 
EOC with PC) (Fig. 1A, B). In all peritoneal metastases, 
a disorganized network of heterogeneous capillaries was 
observed (Fig. 1C, D). The microvasculature surrounding 
metastases showed functional, parallel-aligned capillaries, 
that originated from the capillaries of normal peritoneum 
and were directed towards the metastases (Fig. 1E, F).
IDF imaging: quantitative analysis of microvascular 
parameters
Video clips of the microvasculature in peritoneum with a 
macroscopically normal aspect and of the microvascula-
ture in peritoneal metastases are shown in the animation 
(Online Resource 1). Quantitative microvascular parameters 
are shown in Table 2. In peritoneum with a macroscopically-
normal aspect, the microvasculature was characterized by 
a high perfusion rate, irrespective the presence of EOC 
and/or PC (Fig. 2). In contrast, perfusion parameters (PPV 
and PVD) and TVD were significantly lower in metastases 
than in peritoneum with a macroscopically-normal aspect 
(Table 2; Fig. 3). No differences in microvascular parameters 
were observed between imaging during primary cytoreduc-
tive surgery or after neo-adjuvant chemotherapy.
Immunohistochemistry
In three different patients with high grade serous carci-
noma (HGSC), imaged tissue sites that were macroscopi-
cally determined to contain EOC metastases were biopsied, 
sectioned and stained (Fig. 4). EOC cells were stained spe-
cifically with anti-PAX8 antibodies [27]. All metastases 
indeed stained for PAX8 protein and all 3 metastases dis-
played high levels of VEGF, CD31-positive endothelial cells 
and expression of HIF-1α (Fig. 4; metastases 1, 2 and 3). In 
all 3 metastases that had been biopsied, IDF imaging showed 
limited perfusion of the microvasculature. The control sam-
ple (peritoneum of a patient with a benign ovarian tumor) 
did not stain for PAX8. Limited staining for VEGF, CD31 
and HIF-1α was observed, especially in the endothelium of 
peritoneal microvessels (Fig. 4; normal peritoneum).
Whole mount 3D light sheet fluorescence 
microscopy
One of the imaged EOC peritoneal metastases was biopsied, 
cleared and immunohistochemically stained for CD31, and 
subsequently analyzed with light sheet fluorescence micros-
copy. Figure 5 shows the 3D image of the metastasis located 
in the submesothelial stroma of the peritoneum. The metas-
tasis distorted the shape of the peritoneal elastic lamina 
(PEL), but did not penetrate it. However, as shown in Fig. 6, 
capillaries from the submesothelial regions underneath the 
PEL were continuous with the capillaries of the metastasis. 
In other words, vascular sprouts were able to penetrate the 
PEL during angiogenesis, but EOC cells were not.
Discussion
The results of our study suggest that (1) the perfusion of 
the microvasculature within peritoneal metastases of EOC 
is poor, (2) HIF-1α and VEGF expression are present in 
peritoneal metastases, (3) the microvascular networks of the 
peritoneum and EOC metastases are continuous through all 
peritoneal layers and (4) the intra-abdominal presence of 
EOC and/or PC does not affect the microvasculature in other 
unaffected regions of the peritoneum.
Tumor vasculature is known to differ widely between 
tumor types and to our knowledge, this is the first time that 
angioarchitecture and abnormalities in blood flow were stud-
ied and quantified in vivo in metastases of EOC [33]. The 
perfusion of the microvasculature in peritoneal metastases 
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Table 1  Characteristics and perioperative parameters of the participants and the disease state
Data are presented as medians and interquartile ranges unless indicated otherwise
EOC epithelial ovarian cancer, PC peritoneal carcinomatosis, FIGO international federation of Gynecology and Obstetrics, CR cytoreductive, 
PCI peritoneal cancer index, PAX8 paired box gene 8, X upper interquartile range value was not available
All participants (n = 23) Benign (n = 3) EOC (n = 10) PC of EOC (n = 10)
Participant characteristics
 Age (years) 69 (58–75) 69 (68–x) 60 (50–72) 66 (71–80)
 Smoking, n (%) 3 (13.0) 1 (33.3) 2.5 (0–21.3) 0 (0–11)
 Diabetes, n (%) 4 (17.3) 1 (33.3) 0 (0) 3 (30)
 Hypertension, n (%) 5 (21.7) 0 (0) 2 (20) 3 (30)
 Cardiovascular event, n (%) 8 (34.8) 2 (66.7) 1 (10) 5 (50)
 History abdominal surgery, n (%) 15 (65.2) 2 (66.7) 8 (80) 5 (50)
Disease characteristics
 Histotype
 Serous, n (%) 15 (65.2) 0 (0) 7 (70) 8 (80)
 Clear-cell, n (%) 1 (4.3) 0 (0) 1 (10) 0 (0)
 Granulosa-cell, n (%) 1 (4.3) 0 (0) 1 (10) 0 (0)
 Mucinous, n (%) 1 (4.3) 0 (0) 1 (10) 1 (10)
 Endometrioid, n (%) 1 (4.3) 0 (0) 0 (0) 0 (0)
 Unknown PAX8-positive, n (%) 1 (4.3) 0 (0) 1 (10) 1 (10)
 Grade, high grade, n (%) 14 (60.9) 0 (0) 6 (60) 8 (80)
 FIGO stage
    Ic, n (%) 4 (17.4) 0 (0) 4 (40) 0 (0)
    IIb, n (%) 1 (4.3) 0 (0) 0 (0) 1 (10)
    IIIc, n (%) 9 (39.1) 0 (0) 2 (20) 7 (70)
    Iva, n (%) 3 (13.0) 0 (0) 1 (10) 2 (20)
    IVb, n (%) 3 (13.0) 0 (0) 3 (30) 0 (0)
 Peritoneal involvement, n (%) 10 (43.5) 0 (0) 0 (0) 10 (100)
 Simplified PCI 3 (0–6.75) 0 (0) 3 (0–3) 7 (5.3–11.5)
 Regionscore 1.5 (0–3.75) 0 (0) 1 (0–2) 5 (3–6.3)
 Chemotherapy, n (%) 15 (65.2) 0 (0) 7 (70) 8 (80)
Surgical characteristics
 Explorative, n (%) 5 (21.7) 3 (100) 2 (20) 0 (0)
 CR post chemotherapy, n (%) 14 (60.9) 0 (0) 6 (60) 8 (80)
 CR in recurrent disease, n (%) 4 (17.3) 0 (0) 2 (20) 2 (20)
Anesthesia
 Intravenous and epidural, n (%) 23 (100) 3 (100) 10 (100) 10 (100)
 Hypotensive event, n (%) 9 (39.1) 0 (0) 5 (50) 4 (40)
 Norepinephrine (mg) 0.3 (0.2–0.4) 0.3 (0.3–x) 0.2 (0.15–0.3) 0.4 (0.2–1.0)
 Ephedrine (mg) 10 (0–20.0) 0 (0) 10 (0–21.3) 12.5 (0–21.3)
Per-operative parameters
 Heart rate (bpm) 64 (57–71) 62 (57–x) 65 (56.3–73.8) 64.5 (55–93)
 Systolic pressure (mmHg) 105 (81–130) 116 (66–x) 93 (77.8–137) 107 (90–125)
 Diastolic pressure (mmHg) 55 (44–70) 67 (38–x) 54.5 (44.3–76) 54 (44–66)
 Mean pressure (mmHg) 69 (54–84) 82 (49–x) 65.5 (50–76) 70 (60–79)
 Core temperature, ºC 36.1 (35.7–36.1) 35.9 (35.4–x) 36.1 (35.6–36.6) 36.1 (35.9–36.4)
 Hemoglobin (mmol/L) 7.4 (6.8–7.9) 8.1 (7.2–x) 7.7 (7.0–8.0) 6.9 (6.6–7.8)
 Hematocrit (fraction) 0.35 (0.32–0.39) 0.39 (0.36–x) 0.35 (0.34–0.40) 0.33 (0.31–0.37)
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Fig. 1  Screenshots from CytoCam—incident dark field imaging of 
the peritoneal microcirculation. Each image represents an imaged 
area of 1.55 × 1.16 mm. A, B The microcirculation (black) in peri-
toneum with a macroscopically normal aspect showing continuous 
blood flow. The vessels were embedded in fat tissue and the angio-
architecture was characterized by an organized network of capillar-
ies. C, D The microcirculation within a peritoneal metastasis of EOC. 
The angioarchitecture was distinctly different from that in unaffected 
peritoneum. The blood flow in the microvasculature was either slug-
gish or absent. E, F The microcirculation surrounding a peritoneal 
metastasis. E Normal peritoneal microvasculature is indicated by NV. 
Parallel-aligned capillaries originate from the normal microvascula-
ture and are directed towards a metastasis. F Parallel-aligned capillar-
ies that originate from the normal vasculature are directed towards a 
metastasis (M). Red line, boundary of the metastasis
Table 2  Quantitative 
microvascular parameters
Data are presented as medians and ranges between brackets
EOC epithelial ovarian cancer, PC peritoneal carcinomatosis, PPV percentage of perfused vessels, PVD 
perfused vessel density, TVD total vessel density
a Parameters were compared







Videos, n 17 55 32 14
PPV (%) 97.9 (95.3–100) 99.3 (90.8–100) 99.3a (92.3–100) 25.7a (17.8–50.1)  < 0.01
PVD (mm/mm2) 7.9 (6.6–15.7) 11.4 (8.2–13.6) 9.8 a (7.5–13.8) 2.1a (0.5–3.2)  < 0.01
TVD (mm/mm2) 8.2 (7.0–17.6) 12.6 (9.5–14.0) 10.6 a (8.4–13.9) 7.2a (3.7–10.7) 0.05
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of EOC is most likely limited by the disorganized network 
of aberrant vascular structures [34]. Other theoretical expla-
nations for the abnormal blood flow are the observed high 
levels of VEGF. High levels of VEGF can result in perme-
able and leaky vessels [8], which may further compromise 
perfusion. Since cancer and hemostasis are strongly related, 
thrombi in the microvasculature may also limit blood flow 
[35, 36]. In the current study, we have observed vessels with 
absent flow in which individual erythrocytes could not be 
discriminated, which is possibly caused by the presence of 
thrombi (Fig. 1C, D).
Our findings of the poor perfusion of the microvascula-
ture in peritoneal metastases provide a possible explana-
tion for the high peritoneal recurrence rate of EOC after 
IV-administered platinum-containing chemotherapy, which 
may be caused by ineffective delivery of insufficient con-
centrations of chemotherapy to peritoneal metastases [37]. 
It is tempting to speculate that the findings of our current 
study also partially explain the efficacy of (hyperthermic) 
intraperitoneal (IP) chemotherapy (HIPEC). It has been 
shown that (H)IPEC reduces the chance of recurrence and 
increases 5-year survival rates in patients with stage III EOC 
[38, 39]. During this procedure, the peritoneum is exposed 
to heated (41 °C) chemotherapy for 1.5 h. In case of poorly 
perfused microvasculature, the restricted blood flow may 
be less able to conduct heat and chemotherapy resulting in 
prolonged or more intense exposure in peritoneal metastases. 
The direct toxic effects of hyperthermia may be increased in 
this way, which is further intensified by the synergistic effect 
of chemotherapy [39].
We also hypothesized that a poorly perfused microvas-
culature in metastases may limit the exchange of oxygen, 
carbon dioxide and nutrients between the tissue and the 
vascular compartment, thus limiting expansive and inva-
sive growth of EOC metastases into the peritoneum [40]. 
Expression of HIF-1α suggests that metastases are in fact 
hypoxic. Oxygen delivery to tissue primarily depends on 
the microvasculature and occurs through the hemody-
namic principles convection and diffusion. Convection is 
Error Bars: 95% CI








Proportion of Perfused Vessels in  
macroscopically normal peritoneum
Fig. 2  Proportion of perfused vessels in peritoneum with a macro-
scopically normal aspect in three groups of patients: 1. benign tumor 
(n = 17 videos), 2. EOC without PC (n = 55 videos) and 3. EOC with 
PC (n  =  32 videos). EOC epithelial ovarian cancer, PC peritoneal 
carcinomatosis
Fig. 3  The microvascular parameters total vessel density, perfused 
vessel density and proportion of perfused vessels in peritoneum with 
a macroscopically normal aspect (n  =  104) compared to peritoneal 
metastases (n  =  14). Significant differences were observed for the 
perfusion parameters and are indicated with *
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quantified by flow, and diffusion is quantified by the spatial 
arrangement of capillaries. The relatively high TVD but 
low perfusion parameters suggest that hypoxia in metasta-
ses is a convection/flow problem, rather than a diffusion/
TVD problem [40].
Three dimensional imaging demonstrated vascular con-
tinuity between the vascular networks of the submesothelial 
stroma and the peritoneal metastasis, across the PEL. The 
metastasis seemed to distort the PEL rather than penetrate 
it (Figs. 5, 6), which is in line with other studies that have 
demonstrated that some metastases do not seem capable of 
penetrating the PEL, whereas other metastases do penetrate 
it [6]. The findings of the current study suggest that blood 
vessel sprouts and in particular the tip cells of these sprouts 
invade the PEL. Proteolysis is needed for tissue invasion and 
tip cells are well equipped for these purposes [41]. Elastin is 
particularly difficult to hydrolyze, and only a few proteases 
are able to do this [42]. Apparently, angiogenesis through the 
PEL is possible, whereas invasion of the metastases through 
the PEL is more difficult.
Finally, an important finding of our study was that the 
presence of EOC does not affect the peritoneal vasculature 
in general (Fig. 2). It is known that tumors can modify the 
microenvironment of the prospective metastatic site, in this 
case the peritoneum, to pre-create an environment more 
favorable for tumor survival and growth [43, 44]. With IDF 
imaging, however, we did not observe an altered or increased 
vasculature in unaffected peritoneum, regardless the intra-
abdominal presence of EOC or peritoneal metastases else-
where. This does not exclude preparation of the microenvi-
ronment by immunologic changes at a cellular level.
Strengths and limitations
This is the first study to assess and quantify the perfusion 
of the microvasculature in peritoneal metastases of EOC. 
In vivo imaging provided additional and crucial information, 
Fig. 4  Immunohistochemical (IHC) staining of PAX8, VEGF, CD31 
and HIF-1α was performed on paraffin sections of 3 IDF-imaged 
peritoneal high grade serous carcinoma metastases (metastases 1, 2 
and 3). Chromogenic IHC-images of PAX8, VEGF and CD31, black 
bars = 100 µm. Fluorescence IHC-images of HIF-1α of an area that 
stained positive for PAX8, white bars = 25 µm. Abbreviations: PAX8, 
paired box gene 8; VEGF, vascular endothelial growth factor; CD31, 
cluster of differentiation 31; HIF-1α, hypoxia inducible factor 1α
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which cannot be obtained with the use of immunohistochem-
istry. Three-dimensional whole tumor imaging provided 
additional information on vascular structures connecting 
the vascular networks of the peritoneum and peritoneal 
metastases. The findings of this study generated hypotheses 
regarding pathophysiology and treatment of peritoneal car-
cinomatosis of EOC.
Limitations of this study include the limited focus 
depth of the CytoCam (max 300 µm), which can limit 
microvascular assessment of deeper vascular structures. 
However, the peritoneum is thin (approximately 50 µm in 
healthy subjects) and peritoneal metastases are small, thus 
very suitable for assessment with the CytoCam. Larger 
metastases may not allow full-depth assessment of their 
microvasculature. In these larger structures, it is likely that 
only the more superficial blood vessels are imaged. 3D 
imaging overcomes the limited focus depth, but provides 
no information on vessel perfusion. Another limitation of 
3D imaging is that it requires clearing of the tissue, which 
is difficult in tumors. A limitation of CD31 staining is that 
endothelial cells are detected, also those which may not 
have formed capillaries yet. IDF imaging overcomes this 
limitation, because in the case of IDF imaging erythrocytes 
are visualized, which can only be present when there is 
flow, meaning that capillary formation must have occurred. 
It cannot be excluded that part of the observed effects is 
caused by neo-adjuvant chemotherapy. However, inter-par-
ticipant differences of microvascular parameters did not 
occur and findings were consistent, irrespective of imaging 
during primary cytoreductive surgery or after neo-adjuvant 
chemotherapy. Also, the number of included participants 
was rather small, but because of the consistency of findings 
in the present study and our previous study [18], the differ-
ences are unlikely to be caused by coincidence.
The prevalence of cardiovascular risk factors in our 
study population was high, but comparable to the preva-
lence in the general population of similar age and gender 
[45]. Cardiovascular disease can affect the microvascula-
ture, but this effect would also be present in normal peri-
toneum and not exclusively in metastases. Therefore, it is 
unlikely that differences between the microvasculature in 
metastases and normal peritoneum were caused by cardio-
vascular disease.
Finally, we visualized the vasculature in parietal peri-
toneum of the abdominal and pelvic wall. Although the 
microvascular anatomy is considered to be comparable 
in parietal and visceral peritoneum, future research is 
needed to investigate whether the vasculature in peritoneal 
metastases on the visceral peritoneum is similar. It is also 
interesting to investigate whether the microvasculature in 
peritoneal metastases of gastro-intestinal tumors is similar, 
or whether our findings are specific for metastases of EOC. 
Fig. 5  Light sheet fluorescence microscopy image of a peritoneal 
metastasis with CD31 staining. Blood vessels are shown in white. 
Boundaries of the metastasis are indicated by yellow arrows, and the 
boundaries of the elastic lamina (C) by red arrows. A Abdominal 
cavity, B submesothelial stroma, C elastic lamina, D submesothelial 
stroma; E abdominal wall. Bar = 200 µm
Fig. 6  Light sheet fluorescence microscopy images of a peritoneal metastasis with CD31 staining. Arrows indicate vessels that originate from 
the submesothelial stroma, pass the elastic lamina, and invade the metastasis. Green dots indicate the boundary of the metastasis. Bar = 200 µm
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In addition, it should be investigated whether HIPEC treat-
ment affects the peritoneal microvasculature and whether 
microvascular parameters of the peritoneum correlate with 
course of disease and response to treatment of PC.
Conclusion
We demonstrated that the perfusion of the microvasculature 
in peritoneal metastases of EOC is limited. Hypoperfusion 
may limit the therapeutic efficacy of IV chemotherapy and 
affect the behavior of EOC metastases on the peritoneum. 
Future studies should investigate whether microvascular 
parameters of the peritoneum correlate with disease outcome 
and response to therapy.
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